Abstract |
Specific lesions of the growth hormone (GH)/ insulin-like growth factor (IGF) axis have been identified in humans, each of which has distinctive auxologic and biochemical features. Measures of circulating IGF-I are useful in diagnosing growth disorders in childhood and in evaluating response to GH therapy. Recombinant human IGF-I is an effective treatment of severe primary IGF deficiency, which is typical of patients with GH receptor defects ( Laron syndrome). Such treatment has been limited to a few severely affected patients. Future studies will provide new insight into IGF-I as treatment and into the nature of growth disorders that involve the IGF axis.
|
Authors | Philippe F Backeljauw, Steven D Chernausek |
Journal | Endocrinology and metabolism clinics of North America
(Endocrinol Metab Clin North Am)
Vol. 41
Issue 2
Pg. 265-82, v
(Jun 2012)
ISSN: 1558-4410 [Electronic] United States |
PMID | 22682630
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Insulin-Like Growth Factor Binding Proteins
- Intercellular Signaling Peptides and Proteins
- Recombinant Proteins
- Somatomedins
- myotrophin
|
Topics |
- Child
- Female
- Growth Disorders
(diagnosis, drug therapy, metabolism)
- Humans
- Insulin-Like Growth Factor Binding Proteins
(blood, physiology)
- Intercellular Signaling Peptides and Proteins
(therapeutic use)
- Laron Syndrome
(drug therapy, metabolism)
- Male
- Recombinant Proteins
(therapeutic use)
- Somatomedins
(deficiency, genetics, therapeutic use)
- Treatment Outcome
|